JAK1 and glioblastoma: The JAK1/2 inhibitor ruxolitinib (Quintás-Cardama et al., 2010) almost completely restored ZIKV infection in GBM lines despite treatment with myeloid cell conditioned media (11b+CM) or IFNβ, whereas in HDB lines, ruxolitinib-induced rescue was incomplete, suggesting that other cytokines present could also be involved.